Patients With Patent Foramen Ovale and Endocardial Device Leads on Apixaban for Prevention of Paradoxical Emboli
Withdrawn before enrolling · Phase 2 · Has a placebo group
Conditions studied: Patent Foramen Ovale, Cardiac Implantable Electronic Device
In brief
Patients with a patent foramen ovale in the setting of endocardially placed cardiac implantable electronic devices such as pacemakers, defibrillators, or resynchronization therapies are likely at higher risk for paradoxical embolic events from device lead thrombus. The investigators are conducting this study to determine if the anticoagulant medication Apixaban is more effective at reducing MRI detected brain lesions compared to placebo.
Key facts
- Study ID
- NCT02378623
- Run by
- Mayo Clinic
- People needed
- 0
- Starts
- 2015-05-01
- Expected to finish
- 2020-01-01
- Last updated by the study team
- 2018-11-16
Who can join
Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Mayo Clinic in Rochester — Rochester, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.